Icahn School of Medicine at Mount Sinai

 

Icahn School of Medicine at Mount Sinai
J

Navigating aGVHD Treatment: Integrating Recent Updates in Clinical Management

By Icahn School of Medicine at Mount Sinai FEATURING James Ferrara
By Icahn School of Medicine at Mount Sinai FEATURING James Ferrara
45 views
May 31, 2024
0 Comments
Login to view comments. Click here to Login
Videos
04:39
2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: TACE ± Lenvatinib + Pembro for Int-Stage HCC - P…

Feat. J. Llovet
16:56
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Sequencing Immunotherapy for Myeloma"

Feat. S. Parekh
05:26
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Indirect Comparison of Linvoseltamab Vs. …

Feat. S. Jagannath
16:52
Icahn School of Medicine at Mount Sinai

Navigating aGVHD Treatment: Integrating Recent Updates in Clinical M…

Feat. J. Ferrara
11:32
Icahn School of Medicine at Mount Sinai

Leveraging Liquid Biopsy in Lung Cancer

Feat. C. Rolfo
16:31
Icahn School of Medicine at Mount Sinai

PanRAF Inhibitors in NSCLC

Feat. R. Veluswamy
15:16
Icahn School of Medicine at Mount Sinai

AACR 2024 Insights: "Linvoseltamab, a BCMA-Targeted BsAb, in Pt…

Feat. S. Jagannath
21:52
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…

Feat. D. Tremblay
10:06
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Outcomes After CAR-T in MM Patients With Ex…

Feat. D. Pan
06:14
Insights from 2023 ASH Annual Meeting

Multiple Myeloma: Inflammatory Biomarkers and Outcomes CAR T-Cell Th…

Feat. D. Pan
03:14
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MyDRUG Sub-Protocol Y3 Results - Selinexor,…

Feat. J. Richter
06:51
Insights from 2023 ASH Annual Meeting

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Feat. D. Tremblay
10:38
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax Improves Response Rates But Not …

Feat. D. Tremblay
03:17
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Highlights From the International Myeloma S…

Feat. J. Richter
15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
44:42
Icahn School of Medicine at Mount Sinai

Managing the Nonreproductive Comorbidities of Polycycstic Ovary Synd…

Feat. A. Dunaif
04:34
Icahn School of Medicine at Mount Sinai

Revisiting the Role of Alkylating Agents in Myeloma: Up-to-Date Evid…

Feat. J. Richter
24:39
Icahn School of Medicine at Mount Sinai

Multiple Myeloma: Adverse Effects of CAR-T

Feat. S. Rajeeve
33:05
Icahn School of Medicine at Mount Sinai

Leveraging SCLC Subtypes and Other Biomarkers

Feat. F. Hirsch
52:39
Yale Cancer Center

Myeloma in 2023: So Many Drugs, Yet So Few Cures

Feat. A. Chari
10:46
Icahn School of Medicine at Mount Sinai

Overview of JAKARTA & JAKARTA2 Trials: Impact of Fedratinib on S…

Feat. J. Waksal
09:47
Icahn School of Medicine at Mount Sinai

What's the Difference? Covalent vs. Non-Covalent BTKis in MCL

Feat. J. Brody
15:31
Icahn School of Medicine at Mount Sinai

Myelofibrosis Treatment Options Beyond the JAK/STAT Pathway

Feat. M. Kremyanskaya
23:07
Icahn School of Medicine at Mount Sinai

Kidney Week 2022: Cell-to-Cell Chats in the Diabetic Kidney Endothel…

Feat. I. Daehn
12:43
Oliver Van Oekelen

Outcomes of MM Pts Progressing After BCMA-Targeted CAR T-Cell Therapy

14:03
ASH 2022 Conference Coverage

ASH 2022 Neurotoxicity With Motor Symptoms After BCMA-Directed CAR-T…

Feat. S. Parekh
09:13
SABCS 2022 Conference Coverage

SABCS 2022 Predictors of Response to Neoadjuvant Chemo in Breast Can…

Feat. N. Bilani
05:07
Icahn School of Medicine at Mount Sinai

TKI in the Management of Advanced HCC

Feat. A. Villanueva
11:42
Icahn School of Medicine at Mount Sinai

Symptom Assessments in Myelofibrosis and How to Examine the Spleen

Feat. M. Kremyanskaya
25:49
Icahn School of Medicine at Mount Sinai

Triplet Regimens in Early Relapse MM: Evolving Treatment Dynamics

Feat. C. Rodriguez